Table 1.
Patients’ characteristics at baseline
| Neuropathic pain aetiology | Total n = 51 (n (%)) |
|---|---|
| CIPN | 31 (61) |
| Chemotherapy | |
| Oxaliplatin | 21 (41) |
| Paclitaxel | 2 (4) |
| Taxotere | 1(2) |
| Bortezomib | 2 (4) |
| Cisplatin | 4(8) |
| Carboplatin | 1(2) |
| Median months since last dose (IQ range) | 11 (8 to 24) |
| Neuropathic scar pain | 10 (20) |
| Neuropathic pain due to other causes | 10 (20) |
| Median months of pain: all causes (IQ range) | 19 (9 to 34) |
| Previous/current cancer diagnosis | 41 (80) |
| Type of cancer | |
| Colorectal | 22 (43) |
| Multiple myeloma | 2 (4) |
| Lung | 3 (6) |
| Ovary | 2 (4) |
| Breast | 12 (23) |
| Cancer status | |
| No recurrence | 33 (65) |
| Local disease | 6 (12) |
| Metastatic disease | 2 (4) |
IQ interquartile, CIPN chemotherapy-induced peripheral neuropathy